DOCSLIB.ORG

2015 Report on Prohibited Substances

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
2015 Report on Prohibited Substances 2015 REPORT ON PROHIBITED SUBSTANCES Compiled by the Racing Medication and Testing Consortium, Supervised by the Advisory Council on Equine Prohibited Substances and Practices of the IFHA Racing Medication and Testing Consortium 821 Corporate Drive, Lexington, KY 40503, USA Phone +1(859) 224-2844 Fax +1(859) 296-3033 rmtcnet.com I. RACING DAY SAMPLES DECLARE TOTAL DECLARE D TOTAL DECLARE DECLARE D POSITIVE TOTAL TOTAL TOTAL BOTH BOTH NUMBER TOTAL DECLARED TOTAL DECLARE D D POSITIVE CASES ON NUMBER NUMBER BOTH URINE & URINE & TOTAL URINE URINE TOTAL BLOOD BLOOD OF DECLARE DECLARE DECLARED POSITIVE DECLARE D POSITIVE POSITIVE CASES ON BOTH OF OF HORSES HORSES URINE & BLOOD BLOOD URINE ONLY ONLY BLOOD ONLY ONLY DECLARE DECLARE D D POSITIVE CASES ON D POSITIVE CASES ON CASES ON BOTH URINE & RACES HORSES SAMPLE SAMPLE BLOOD SAMPLE SAMPLE ONLY SAMPLE SAMPLE ONLY SAMPLE SAMPLE D D POSITIVES POSITIVE CASES ON URINE POSITIVE CASES ON BLOOD BOTH URINE & BLOOD (flat & SAMPLE D PRE- D POST- SAMPLE D PRE- D POST- SAMPLE D PRE- D POST- SAMPLE D PRE- D POST- POSITIVE POSITIVES POST- CASES ON URINE PRE- POST- CASES ON BLOOD POST- URINE & BLOOD POST- SUBSTANCES DETECTED IN COUNTRY jumps) D RACE RACE D RACE RACE D RACE RACE D RACE RACE CASES PRE-RACE RACE URINE RACE RACE BLOOD PRE-RACE RACE BLOOD PRE-RACE RACE OTHER HORSE COMPETITIONS Argentina 5,568 12,147 0 12,147 82 0 82 11,316 0 11,316 749 0 749 129 0 129 128 0 128 0 0 1 129 0 129 Australia 18,949 46,392 3,547 42,845 0 0 0 18,703 0 18,703 27,689 3,547 24,142 87 1 86 65 0 65 22 1 21 87 1 86 Austria 0000 00000 000 Bahrain 187 1,947 1,722 225 0 00127 0 127 1,820 1,722 98 5052 023 03 505 Belgium 171 86 08677 0773 036 06 0000 000 00 000 Brazil (Brasileiro/RJ) 1,800 2,113 0 2,113 1,111 0 1,111 969 0 969 33 033 8086 062 02 808 Brazil (Sao Paulo) 0000 00000 000 Chile 1,637 2,475 0 2,475 0 002,080 0 2,080 395 0 395 14 0 14 14 0140 0014 0 14 China (Hong Kong) 796 12,198 10,115 2,083 2,062 0 2,062 9,994 9,994 0 142 121 21 4223 211 01422 Croatia 0000 00000 000 Cyprus 1,030 1,074 0 1,074 0 001,074 0 1,074 0 0011 0 11 11 0110 0011 0 11 Czech Republic 485 43 04343 04324 02419 019 4044 040 00404 Denmark 0000 00000 000 France 7,318 10,911 0 10,911 9,725 0 9,725 0 001,186 0 1,186 26 0 26 20 0206 0626 0 26 Germany 1,316 450 0 450 1 01340 0 340 109 0 109 3033 030 00303 Greece 0000 00000 000 Hungary 0000 00000 000 India 3,145 2,977 0 2,977 0 002,977 0 2,977 0 0021 0 21 21 0210 0021 0 21 India (DRC) 314 174 0 174 0 00174 0 174 0 00 7077 070 00707 India (MRC) 552 5 050 005 050 00 2022 020 00202 India (RWITC) 592 761 0 761 0 00761 0 761 0 00 8088 080 00808 Ireland 2,522 2,608 0 2,608 0 002,024 0 2,024 584 0 584 4044 040 00404 Italy 0000 00000 000 Japan (JRA) 3,454 10,374 0 10,374 2,541 0 2,541 7,569 0 7,569 264 0 264 1011 010 00101 Japan (NAR) 12,723 29,807 0 29,807 0 0026,035 0 26,035 3,772 0 3,772 2022 020 00202 Lebanon 366 393 0 393 25 025340 0 340 15 015 8088 080 00808 Macau 0000 00000 000 Malaysia 595 8,923 6,854 2,069 2,023 0 2,023 0 006,900 6,854 46 11 0 11 10 0101 0111 0 11 Mauritius 280 2,667 2,377 290 298 0 298 2,657 2,377 280 5 05 3303 300 00330 Mexico 0000 00000 000 Morocco 2,248 4,345 0 4,345 12 0122,485 0 2,485 1,848 0 1,848 17 0 17 15 0152 0217 0 17 the Netherlands 788 378 64 314 4 04148 0 148 230 64 166 3030 003 03303 New Zealand 2,848 3,489 491 2,998 0 002,356 0 2,356 1,133 491 642 0000 000 00000 Norway 0000 00000 000 Oman 162 812 0 812 199 0 199 0 00613 0 613 22 0 22 14 0148 0822 0 22 Panama 0000 00000 000 Peru 1,929 1,989 0 1,989 0 001,160 0 1,160 829 0 829 11 0 11 0 0011 01111 0 11 Poland 626 223 0 223 14 014155 0 155 54 054 2022 020 00202 Qatar 0000 00000 000 Saudi Arabia 0000 00000 000 Serbia 0000 00000 000 Singapore 928 13,201 10,381 2,820 2,759 0 2,759 0 0010,442 10,381 61 4042 022 02404 Slovakia 0000 00000 000 South Africa 3,840 5,084 480 4,604 0 004,342 0 4,342 742 480 262 15 3 12 10 0105 3215 3 12 Spain 129 188 0 188 2 02164 0 164 22 022 1011 010 00101 Sweden 0000 00000 000 Switzerland 178 85 08539 0391 0145 045 0000 000 00000 Tunisia 474 535 0 535 0 00306 0 306 229 0 229 3031 012 02303 Turkey 5,426 11,856 115 11,741 0 0010,779 0 10,779 1,077 115 962 63 0 63 59 0594 0463 0 63 United Arab Emirates 376 4,267 3,333 934 0 00887 0 887 3,380 3,333 47 8355 053 30835 United Kingdom 10,041 8,670 195 8,475 479 0 479 6,375 0 6,375 1,816 195 1,621 14 0 14 13 0131 0114 0 14 USA** 90,378 0 0 174,347 174,347 195,806 195,806 0 0 0 0 0 1,371 0 1,371 Uruguay 1,931 3,581 0 3,581 0 003,485 0 3,485 96 09621 0 21 21 0210 0021 0 21 **Information as provided by ARCI, some information may be imcomplete. I. RACING DAY SAMPLES REACTION PROHIBTED SUBSTANCES DETECTED ENGENDERED COUNTRIES OF DETECTION TOTAL 2,5-Dihydroxybenzenesulfonate (component of Hemostatic etamsylate) 2-(1-Hydroxyethyl) Promazine Sulfoxide (Promazine Neuroleptic, Metabolite) Tranquilizer Muscle relaxant, anti- 3 Desmethyl Thiocolchinine inflamatory 3-Hydroxylidocaine (metabolite of lidocaine) Local Anesthetic CY (1) 1 3-hydroxy-N-methylmorphinan Opioid MY (3) 3 3-OH-Lidocaine (Lidocaine metabolite) Local Anesthetic Various function in 3-methoxytyramine (metabolite of dopamine) US (1) 1 nervous system 4-(Dimethylamino)-antipyrine Analgesic 4-Aminoantipyrine Analgesic 4-Hydroxy Xylazine (Xylazine Metabolite) Sedative, Analgesic 4-Methyl-Aminoantipyrine Analgesic IN (1) 1 4-Methyl-Aminoantipyrine, Phenylbutazone, Analgesic, Anti- oxyphenbutazone Inflammatory 4-Methylamino Phenazone 4-OH Propranolol Beta Blacker 5-Alpha-estrane 3-beta 17-Alpha-diol and nandrolone 6 alpha-methylprednisolone Active principle of 9-carboxy-11-nor-delta-9-TCH marijuana 16 beta-idrossistanozolol Anabolic Glucocorticoid, Anti- 20-Beta-dihydro-prednisolone Inflammatory Aicar Blood Doping Anti-Coagulant, Acenocoumarol Vitamin K Antagonist Acepromazine Tranquilizer LB (1), TR (1), UK (1), AR (2) 5 Acepromazine metabolites Tranquilizer Tranquilizer, Acepromazine, Hydroxyethyl Promazine Sulphoxide Neuroleptic Tranquilizer, Anti- Acepromazine, flunixin Inflammatory, Analgesic Acetaminophen Analgesic PE (1) 1 Acetophenazine Antipsychotic Acetylsalicylic acid NL (1) 1 Acide 2- Tenoique Local antiseptic Acide tolfenamique MA (1) 1 Albuterol Bronchodilator Alfentanil Opioid, Analgesic Anxiolytic, Sedative, Alprazolam Muscle Relaxant (skeletal) Altrenogest Progestogen FR (1) 1 Ambroxol mucolytic agent TR (1), OM (2), AR (1) 4 mucolytic agent, Ambroxol, furosemide diuretic Aminocaproic Acid Hemostatic LB (1) 1 Aminorex Stimulant I. RACING DAY SAMPLES Tricyclic Anti- Amitriptylline Depressant Amphetamine Stimulant AU (1), FR (1) 2 Selective Androgen Andarine (S-4) Receptor Modulator Antipyretic, Antipyrine IN (1), IN-DRC (1) 2 Analgesic Analgesic, Antipyrine, Dipyrone Antispasmodic Arsenic Toxic element AU (10), FR (1), MA (1) 12 Beta-1 Receptor Atenolol IN-DRC (2), FR (1), AR (13) 16 Antagonist Beta-1 Receptor Atenolol and Diclofenac Antagonist, anti- inflammatory Beta-1 Receptor Antagonist, Atenolol and Phenylbutazone Analgesic, Anti- Inflammatory Atropine Anticholinergic AR (4) 4 Barbital Hypnotic Beclomethasone TR (1) 1 BEG Benzocaine Topical Anesthetic Benzoylecgonine CNS Stimulant CY (3) 3 Benzoylecgonine ecgonine methyl ester CNS Stimulant Glucocorticoid, Anti- Betamethasone CY (1), TN (1), PE (1), SG (2) 5 Inflammatory Glucocorticoid, Anti- Betamethasone, dexamethasone Inflammatory Boldenone Anabolic IN (1), IN-DRC (1), IN-RWITC (1), PE (1) 4 Boldenone Sulphate (metabolite of boldenone) Anabolic Anabolic, Anti- Boldenone, Flunixin Inflammatory, Analgesic Bromazepam Minor Tranquilizer AR (2) 2 Expectorant, Bromhexine Mucolytic Bupivacaine Local Anesthetic Buspirone Anxiolytic Butazolidine, furosemide NSAID, Diuretic Analgesic, Butorphanol UK (1), AE (1), AR (5), UY (1) 8 Antitussive Antispasmodic, Butylescopolamine Muscarinic TR (1) 1 Antagonist Butylscopolammonium Anti-Spasmodic Butylscopolammonium bromide Anti-Spasmodic BZEG (metabolite of cocaine) Local Anesthetic Cardiac & AU (3), TR (4), IN (1), CZ (2), IE (1), FR (2), ZA Caffeine Respiratory (2), PE (1), MY (1), JN-NAR (2), PL (1), AE (1), 64 Stimulant US (13), AR (16), UY (12), CL (2) Caffeine, Mephentermine Cardiac & Caffeine nikethamide Respiratory Stimulant I. RACING DAY SAMPLES Cardiac & Caffeine metabolites Respiratory Stimulant Cardiac & Respiratory Caffeine, Theophylline Stimulant, Cardiac Stimulant, Vasodilator, Diuretic Caffeine, Clenbuterol, Firocoxib Cardiac & Respiratory Stimulant; Caffeine, cyproheptadine, paraxantheme, theophylline Antihistaminic, Antipruritic, Sedative; Vasodilator, Diuretic Cardiac & Respiratory Caffeine, Dexametasone, 4-Aminoantipyrine, 4-Methyl- Stimulant, Aminoantipyrine Glucocorticoid, Anti- Inflammatory, Analgesic Cardiac & Respiratory Stimulant, Caffeine, theobromine, theophylline Myocaridal Stimulant, Vasodilator, Diuretic Cardiac & Respiratory Caffeine, paraxanthine (caffeine metabolite), Stimulant, theobromine, theophylline Myocaridal Stimulant, Vasodilator, Diuretic Cardiac & Respiratory Stimulant, Caffeine, theobromine Myocardial Stimulant, Weak Diuretic Cardiac & Respiratory Caffeine, theophylline Stimulant, Vasodilator, Diuretic Cannabinol + Tetrahycrocannabinol LB (2) 2 Capsaicin Topical Analgesic BR-RJ (1) Capsaicin, dihydrocapsaicin Topical Analgesic Capsaicin hydroxy dantrolene salbutamol IE(not specified) Carbazochrome Antihemorrhagic BR-RJ (1) 1 Carboprotol US (1) 1 Carisoprodol Muscle Relaxant Carprofen ZA (2) 2 Cathinone IN (1), IN-RWITC (1) 2 I.
Load more

Recommended publications
  • Medical Review(S) Clinical Review
    CENTER FOR DRUG EVALUATION AND RESEARCH APPLICATION NUMBER: 200327 MEDICAL REVIEW(S) CLINICAL REVIEW Application Type NDA Application Number(s) 200327 Priority or Standard Standard Submit Date(s) December 29, 2009 Received Date(s) December 30, 2009 PDUFA Goal Date October 30, 2010 Division / Office Division of Anti-Infective and Ophthalmology Products Office of Antimicrobial Products Reviewer Name(s) Ariel Ramirez Porcalla, MD, MPH Neil Rellosa, MD Review Completion October 29, 2010 Date Established Name Ceftaroline fosamil for injection (Proposed) Trade Name Teflaro Therapeutic Class Cephalosporin; ß-lactams Applicant Cerexa, Inc. Forest Laboratories, Inc. Formulation(s) 400 mg/vial and 600 mg/vial Intravenous Dosing Regimen 600 mg every 12 hours by IV infusion Indication(s) Acute Bacterial Skin and Skin Structure Infection (ABSSSI); Community-acquired Bacterial Pneumonia (CABP) Intended Population(s) Adults ≥ 18 years of age Template Version: March 6, 2009 Reference ID: 2857265 Clinical Review Ariel Ramirez Porcalla, MD, MPH Neil Rellosa, MD NDA 200327: Teflaro (ceftaroline fosamil) Table of Contents 1 RECOMMENDATIONS/RISK BENEFIT ASSESSMENT ......................................... 9 1.1 Recommendation on Regulatory Action ........................................................... 10 1.2 Risk Benefit Assessment.................................................................................. 10 1.3 Recommendations for Postmarketing Risk Evaluation and Mitigation Strategies ........................................................................................................................
    [Show full text]
  • The National Drugs List
    ^ ^ ^ ^ ^[ ^ The National Drugs List Of Syrian Arab Republic Sexth Edition 2006 ! " # "$ % &'() " # * +$, -. / & 0 /+12 3 4" 5 "$ . "$ 67"5,) 0 " /! !2 4? @ % 88 9 3: " # "$ ;+<=2 – G# H H2 I) – 6( – 65 : A B C "5 : , D )* . J!* HK"3 H"$ T ) 4 B K<) +$ LMA N O 3 4P<B &Q / RS ) H< C4VH /430 / 1988 V W* < C A GQ ") 4V / 1000 / C4VH /820 / 2001 V XX K<# C ,V /500 / 1992 V "!X V /946 / 2004 V Z < C V /914 / 2003 V ) < ] +$, [2 / ,) @# @ S%Q2 J"= [ &<\ @ +$ LMA 1 O \ . S X '( ^ & M_ `AB @ &' 3 4" + @ V= 4 )\ " : N " # "$ 6 ) G" 3Q + a C G /<"B d3: C K7 e , fM 4 Q b"$ " < $\ c"7: 5) G . HHH3Q J # Hg ' V"h 6< G* H5 !" # $%" & $' ,* ( )* + 2 ا اوا ادو +% 5 j 2 i1 6 B J' 6<X " 6"[ i2 "$ "< * i3 10 6 i4 11 6! ^ i5 13 6<X "!# * i6 15 7 G!, 6 - k 24"$d dl ?K V *4V h 63[46 ' i8 19 Adl 20 "( 2 i9 20 G Q) 6 i10 20 a 6 m[, 6 i11 21 ?K V $n i12 21 "% * i13 23 b+ 6 i14 23 oe C * i15 24 !, 2 6\ i16 25 C V pq * i17 26 ( S 6) 1, ++ &"r i19 3 +% 27 G 6 ""% i19 28 ^ Ks 2 i20 31 % Ks 2 i21 32 s * i22 35 " " * i23 37 "$ * i24 38 6" i25 39 V t h Gu* v!* 2 i26 39 ( 2 i27 40 B w< Ks 2 i28 40 d C &"r i29 42 "' 6 i30 42 " * i31 42 ":< * i32 5 ./ 0" -33 4 : ANAESTHETICS $ 1 2 -1 :GENERAL ANAESTHETICS AND OXYGEN 4 $1 2 2- ATRACURIUM BESYLATE DROPERIDOL ETHER FENTANYL HALOTHANE ISOFLURANE KETAMINE HCL NITROUS OXIDE OXYGEN PROPOFOL REMIFENTANIL SEVOFLURANE SUFENTANIL THIOPENTAL :LOCAL ANAESTHETICS !67$1 2 -5 AMYLEINE HCL=AMYLOCAINE ARTICAINE BENZOCAINE BUPIVACAINE CINCHOCAINE LIDOCAINE MEPIVACAINE OXETHAZAINE PRAMOXINE PRILOCAINE PREOPERATIVE MEDICATION & SEDATION FOR 9*: ;< " 2 -8 : : SHORT -TERM PROCEDURES ATROPINE DIAZEPAM INJ.
    [Show full text]
  • Ionization Energies of Benzodiazepines Salvatore Millefiori, Andrea Alparone
    Electronic properties of neuroleptics: ionization energies of benzodiazepines Salvatore Millefiori, Andrea Alparone To cite this version: Salvatore Millefiori, Andrea Alparone. Electronic properties of neuroleptics: ionization energies of benzodiazepines. Journal of Molecular Modeling, Springer Verlag (Germany), 2010, 17 (2), pp.281- 287. 10.1007/s00894-010-0723-7. hal-00590996 HAL Id: hal-00590996 https://hal.archives-ouvertes.fr/hal-00590996 Submitted on 6 May 2011 HAL is a multi-disciplinary open access L’archive ouverte pluridisciplinaire HAL, est archive for the deposit and dissemination of sci- destinée au dépôt et à la diffusion de documents entific research documents, whether they are pub- scientifiques de niveau recherche, publiés ou non, lished or not. The documents may come from émanant des établissements d’enseignement et de teaching and research institutions in France or recherche français ou étrangers, des laboratoires abroad, or from public or private research centers. publics ou privés. Editorial Manager(tm) for Journal of Molecular Modeling Manuscript Draft Manuscript Number: JMMO1191R1 Title: Electronic properties of neuroleptics: ionization energies of benzodiazepines Article Type: Original paper Keywords: Benzodiazepines; vertical ionization energies; vertical electron affinities; DFT calculations; electron propagator theory calculations. Corresponding Author: Prof. Salvatore Millefiori, Corresponding Author's Institution: First Author: Salvatore Millefiori Order of Authors: Salvatore Millefiori; Andrea Alparone Abstract: Abstract. Vertical ionization energies (VIEs) of medazepam and nordazepam and of their molecular subunits have been calculated with the electron propagator method in the P3/CEP-31G* approximation. Vertical electron affinities (VEAs) have been obtained with a ΔSCF procedure at the DFT-B3LYP/6-31+G* level of theory. Excellent correlations have been achieved between IEcalc and IEexp allowing reliable assignment of the ionization processes.
    [Show full text]
  • Product List March 2019 - Page 1 of 53
    Wessex has been sourcing and supplying active substances to medicine manufacturers since its incorporation in 1994. We supply from known, trusted partners working to full cGMP and with full regulatory support. Please contact us for details of the following products. Product CAS No. ( R)-2-Methyl-CBS-oxazaborolidine 112022-83-0 (-) (1R) Menthyl Chloroformate 14602-86-9 (+)-Sotalol Hydrochloride 959-24-0 (2R)-2-[(4-Ethyl-2, 3-dioxopiperazinyl) carbonylamino]-2-phenylacetic 63422-71-9 acid (2R)-2-[(4-Ethyl-2-3-dioxopiperazinyl) carbonylamino]-2-(4- 62893-24-7 hydroxyphenyl) acetic acid (r)-(+)-α-Lipoic Acid 1200-22-2 (S)-1-(2-Chloroacetyl) pyrrolidine-2-carbonitrile 207557-35-5 1,1'-Carbonyl diimidazole 530-62-1 1,3-Cyclohexanedione 504-02-9 1-[2-amino-1-(4-methoxyphenyl) ethyl] cyclohexanol acetate 839705-03-2 1-[2-Amino-1-(4-methoxyphenyl) ethyl] cyclohexanol Hydrochloride 130198-05-9 1-[Cyano-(4-methoxyphenyl) methyl] cyclohexanol 93413-76-4 1-Chloroethyl-4-nitrophenyl carbonate 101623-69-2 2-(2-Aminothiazol-4-yl) acetic acid Hydrochloride 66659-20-9 2-(4-Nitrophenyl)ethanamine Hydrochloride 29968-78-3 2,4 Dichlorobenzyl Alcohol (2,4 DCBA) 1777-82-8 2,6-Dichlorophenol 87-65-0 2.6 Diamino Pyridine 136-40-3 2-Aminoheptane Sulfate 6411-75-2 2-Ethylhexanoyl Chloride 760-67-8 2-Ethylhexyl Chloroformate 24468-13-1 2-Isopropyl-4-(N-methylaminomethyl) thiazole Hydrochloride 908591-25-3 4,4,4-Trifluoro-1-(4-methylphenyl)-1,3-butane dione 720-94-5 4,5,6,7-Tetrahydrothieno[3,2,c] pyridine Hydrochloride 28783-41-7 4-Chloro-N-methyl-piperidine 5570-77-4
    [Show full text]
  • New Rules Pertaining to the Banning of Anabolic Steroids in the Western Australian Harness Racing Industry to Be Introduced 1St September 2014
    NEW RULES PERTAINING TO THE BANNING OF ANABOLIC STEROIDS IN THE WESTERN AUSTRALIAN HARNESS RACING INDUSTRY TO BE INTRODUCED 1ST SEPTEMBER 2014 Notice is hereby given that the Board of Racing and Wagering WA have resolved that the RWWA Rules of Harness Racing 2004 be amended. In accordance with section 45 (1) (b) of the Racing and Wagering Western Australia Act 2003 the Board of Racing and Wagering WA on the 10th April 2014 resolved that these amendments be adopted accordingly into the RWWA Rules of Harness Racing. The Harness Racing Board had advised of these amendments and the RWWA Board has determined that these amendments will come into effect on 1st September 2014. The details of the relevant rules pertaining to this ban of anabolic steroids for reference can be found following this advice. There are many implications arising from the introduction of these rules, and to assist trainers and veterinarians to comply with the new rules the following explanatory statement has been prepared. Which steroids are banned under these rules? The new rules ban the use of "anabolic androgenic steroids" in Standardbred horses at any time from birth until retirement. "Anabolic androgenic steroids" include those that are currently registered in Australia by the APVMA for use in horses, such as boldenone, ethylestrenol (in Nitrotain), methandriol, nandrolone, stanozolol and testosterone. Exogenous anabolic androgenic steroids that are banned also include but are not limited to those listed in the WADA prohibited list, such as 1-androstenediol; 1-androstenedione;
    [Show full text]
  • The Effect of Morphine-Lidocaine-Ketamine
    THE EFFECT OF MORPHINE-LIDOCAINE-KETAMINE- DEXMEDETOMIDINE CO-INFUSION ON MINIMUM ALVEOLAR CONCENTRATION OF ISOFLURANE IN DOGS Thesis Presented in Partial Fulfillment of the Requirements for the Degree of Master of Science in the Graduate School of The Ohio State University By Lisa Michelle Sams, D.V.M. Graduate Program in Comparative and Veterinary Medicine The Ohio State University 2011 Thesis Committee: Dr. Phillip Lerche, Advisor Dr. Richard M. Bednarski Dr. John A.E. Hubbell Copyright by Lisa Michelle Sams 2011 ABSTRACT The purpose of this study was to determine the effects of an infusion of dexmedetomidine, a co-infusion of morphine-lidocaine-ketamine (MLK), and a co- infusion of dexmedetomidine-morphine-lidocaine-ketamine (alpha-MLK) on minimum alveolar concentration (MAC) of isoflurane in dogs. The MAC of an inhalant anesthetic required to prohibit purposeful movement is a measure of anesthetic potency (Eger et al 1965). Isoflurane is the most commonly used inhalant anesthetic in veterinary practice (Lozano et al 2009), but has potent vasodilatory effects and causes a dose-dependent decrease in mean arterial pressure in anesthetized dogs (Steffey and Howland 1977). Additional drugs are used during anesthesia to decrease the inhalant anesthetic requirement, a concept referred to as balanced anesthesia. Each of the drugs we infused has a different central nervous system receptor mechanism of action. Co-infusion of MLK, as well as the infusion of each drug separately, has been shown to reduce MAC in isoflurane-anesthetized dogs (Muir et al 2003). Dexmedetomidine, an alpha-2 agonist, has been shown to reduce isoflurane MAC in dogs (Pascoe et al 2006).
    [Show full text]
  • Irina Nicoleta Cimalla Algan/Gan Sensors for Direct Monitoring Of
    Irina Nicoleta Cimalla AlGaN/GaN sensors for direct monitoring of fluids and bioreactions AlGaN/GaN sensors for direct monitoring of fluids and bioreactions Irina Nicoleta Cimalla Universitätsverlag Ilmenau 2011 Impressum Bibliografische Information der Deutschen Nationalbibliothek Die Deutsche Nationalbibliothek verzeichnet diese Publikation in der Deutschen Nationalbibliografie; detaillierte bibliografische Angaben sind im Internet über http://dnb.d-nb.de abrufbar. Diese Arbeit hat der Fakultät für Elektrotechnik und Informationstechnik der Technischen Universität Ilmenau als Dissertation vorgelegen. Tag der Einreichung: 23. November 2009 1. Gutachter: PD Dr. rer. nat. habil. Andreas Schober (Technische Universität Ilmenau) 2. Gutachter: Univ.-Prof. Dr. rer. nat. habil. Oliver Ambacher (Fraunhofer Institut für Angewandte Festkörperphysik Freiburg) 3. Gutachter: PD Dr.-Ing. habil. Frank Schwierz (Technische Universität Ilmenau) Tag der Verteidigung: 15. Juli 2010 Technische Universität Ilmenau/Universitätsbibliothek Universitätsverlag Ilmenau Postfach 10 05 65 98684 Ilmenau www.tu-ilmenau.de/universitaetsverlag Herstellung und Auslieferung Verlagshaus Monsenstein und Vannerdat OHG Am Hawerkamp 31 48155 Münster www.mv-verlag.de ISBN 978-3-86360-003-7 (Druckausgabe) URN urn:nbn:de:gbv:ilm1-2010000519 Titelfoto: photocase.com | AlexFlint „Unde dragoste nu e, nimic nu e” „Wo Liebe nicht ist, ist gar nichts“ Marin Preda: „Cel mai iubit dintre pamanteni“ 5 6 Abstract In this thesis, AlGaN/GaN heterostructures, which have shown to be reliable pH sensors, have been characterized and further developed for the in situ monitoring of cell reactions. For this reason, NG108-15 nerve cells were cultivated on sensor surfaces and their response on different neuroinhibitors was clearly monitored. First, a measurement setup for extracellular recording was designed in connection with an improved chip design and sensor technology.
    [Show full text]
  • Classical Recreational Drugs New Psychoactive Substances
    . Euro-DEN Plus: 2013-2017 . 23,947 presentations Classical Recreational Drugs and New Psychoactive Substances Professor Paul I Dargan Guy’s and St Thomas’ NHS Foundation Trust and King’s College London London, UK “Classical Drugs” Classification Stimulants Depressants MDMA (ecstasy) Opioids Amphetamine Benzodiazepines Cocaine GHB/GBL/1,4BD Hallucinogenics LSD Ketamine 1 Opioid Antagonist – Naloxone GHB and its Analogues GBL / 1,4BD . Competitive opioid antagonist – Onset 1-2 minutes, duration 30-90 minutes . Give in titrated 100 – 200 micrograms doses . Naloxone should be given IV – Can be given IM if no IV access . Aim to restore normal oxygenation/improve alertness . Infusion if long-acting preparation / features recur – Initial hourly dose of infusion is 2/3 of initial dose . What additional test is important in everyone with opioid toxicity? Paracetamol concentration . Ingestion of all 3 causes similar clinical features Effects of GHB / GBL Management of acute GHB/GBL toxicity 1-2mL . Mild-Moderate: – relaxation, appreciation for music & dancing, euphoria . Supportive care: ABC and monitoring – nausea, tremor, diarrhoea, agitation . Coma normally lasts 1-3 hours 3-4mL . Severe: . Airway reflexes generally well maintained – Increasing drowsiness …. coma, convulsions, respiratory depression, . Need for intubation: bradycardia – Not usually indicated if maintaining airway, no vomiting NB. Vomiting in 15-20%, convulsions in <10% . Think about dependence / risk of withdrawal in those with acute toxicity 3-6mL . Deaths: – Mostly pre-hospital, related to aspiration How many have seen a patient with this? 2 GHB Dependence/Withdrawal Acute Stimulant Toxicity . GHB: GABA-B agonist, also upregulates dopamine . Agitation and aggression, psychosis . Very frequent use: 1-2 hourly including overnight .
    [Show full text]
  • Families and the Structural Relatedness Among Globular Proteins
    Protein Science (1993), 2, 884-899. Cambridge University Press. Printed in the USA. Copyright 0 1993 The Protein Society -~~ ~~~~ ~ Families and the structural relatedness among globular proteins DAVID P. YEE AND KEN A. DILL Department of Pharmaceutical Chemistry, University of California, San Francisco, California94143-1204 (RECEIVEDJanuary 6, 1993; REVISEDMANUSCRIPT RECEIVED February 18, 1993) Abstract Protein structures come in families. Are families “closely knit” or “loosely knit” entities? We describe a mea- sure of relatedness among polymer conformations. Based on weighted distance maps, this measure differs from existing measures mainly in two respects: (1) it is computationally fast, and (2) it can compare any two proteins, regardless of their relative chain lengths or degree of similarity. It does not require finding relative alignments. The measure is used here to determine the dissimilarities between all 12,403 possible pairs of 158 diverse protein structures from the Brookhaven Protein Data Bank (PDB). Combined with minimal spanning trees and hier- archical clustering methods,this measure is used to define structural families. It is also useful for rapidly searching a dataset of protein structures for specific substructural motifs.By using an analogy to distributions of Euclid- ean distances, we find that protein families are not tightly knit entities. Keywords: protein family; relatedness; structural comparison; substructure searches Pioneering work over the past 20 years has shown that positions after superposition. RMS is a useful distance proteins fall into families of related structures (Levitt & metric for comparingstructures that arenearly identical: Chothia, 1976; Richardson, 1981; Richardson & Richard- for example, when refining or comparing structures ob- son, 1989; Chothia & Finkelstein, 1990).
    [Show full text]
  • EUROPEAN COMMISSION Brussels, 11.7.2011 SEC(2011)
    EUROPEAN COMMISSION Brussels, 11.7.2011 SEC(2011) 912 final COMMISSION STAFF WORKING PAPER on the assessment of the functioning of Council Decision 2005/387/JHA on the information exchange, risk assessment and control of new psychoactive substances Accompanying the document REPORT FROM THE COMMISSION on the assessment of the functioning of Council Decision 2005/387/JHA on the information exchange, risk assessment and control of new psychoactive substances {COM(2011) 430 final} EN EN TABLE OF CONTENTS 1. Introduction...................................................................................................................3 2. Methodology.................................................................................................................4 3. Key findings from the 2002 evaluation of the Joint Action on synthetic drugs ...........5 4. Overview of notifications, types of substances and trends at EU level 2005-2010......7 5. Other EU legislation relevant for the regulation of new psychoactive substances.....12 6. Functioning of the Council Decision on new psychoactive substances .....................16 7. Findings of the survey among Member States............................................................17 7.1. Assessment of the Council Decision ..........................................................................17 7.2. Stages in the functioning of the Council Decision .....................................................18 7.3. National responses to new psychoactive substances ..................................................20
    [Show full text]
  • Pharmacy and Poisons (Third and Fourth Schedule Amendment) Order 2017
    Q UO N T FA R U T A F E BERMUDA PHARMACY AND POISONS (THIRD AND FOURTH SCHEDULE AMENDMENT) ORDER 2017 BR 111 / 2017 The Minister responsible for health, in exercise of the power conferred by section 48A(1) of the Pharmacy and Poisons Act 1979, makes the following Order: Citation 1 This Order may be cited as the Pharmacy and Poisons (Third and Fourth Schedule Amendment) Order 2017. Repeals and replaces the Third and Fourth Schedule of the Pharmacy and Poisons Act 1979 2 The Third and Fourth Schedules to the Pharmacy and Poisons Act 1979 are repealed and replaced with— “THIRD SCHEDULE (Sections 25(6); 27(1))) DRUGS OBTAINABLE ONLY ON PRESCRIPTION EXCEPT WHERE SPECIFIED IN THE FOURTH SCHEDULE (PART I AND PART II) Note: The following annotations used in this Schedule have the following meanings: md (maximum dose) i.e. the maximum quantity of the substance contained in the amount of a medicinal product which is recommended to be taken or administered at any one time. 1 PHARMACY AND POISONS (THIRD AND FOURTH SCHEDULE AMENDMENT) ORDER 2017 mdd (maximum daily dose) i.e. the maximum quantity of the substance that is contained in the amount of a medicinal product which is recommended to be taken or administered in any period of 24 hours. mg milligram ms (maximum strength) i.e. either or, if so specified, both of the following: (a) the maximum quantity of the substance by weight or volume that is contained in the dosage unit of a medicinal product; or (b) the maximum percentage of the substance contained in a medicinal product calculated in terms of w/w, w/v, v/w, or v/v, as appropriate.
    [Show full text]
  • Wo 2010/075090 A2
    (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (10) International Publication Number (43) International Publication Date 1 July 2010 (01.07.2010) WO 2010/075090 A2 (51) International Patent Classification: (81) Designated States (unless otherwise indicated, for every C07D 409/14 (2006.01) A61K 31/7028 (2006.01) kind of national protection available): AE, AG, AL, AM, C07D 409/12 (2006.01) A61P 11/06 (2006.01) AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, (21) International Application Number: DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, PCT/US2009/068073 HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, (22) International Filing Date: KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, 15 December 2009 (15.12.2009) ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, RO, RS, RU, SC, SD, (25) Filing Language: English SE, SG, SK, SL, SM, ST, SV, SY, TJ, TM, TN, TR, TT, (26) Publication Language: English TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (30) Priority Data: (84) Designated States (unless otherwise indicated, for every 61/122,478 15 December 2008 (15.12.2008) US kind of regional protection available): ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, (71) Applicant (for all designated States except US): AUS- ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, PEX PHARMACEUTICALS, INC.
    [Show full text]